UBS Group’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1
| Closed | -$1 | – | 10461 |
|
|
2023
Q4 | $1 | Sell |
1
-101
| -99% | -$86 | ﹤0.01% | 9218 |
|
|
2023
Q3 | $114 | Buy |
102
+101
| +10,100% | +$126 | ﹤0.01% | 8854 |
|
|
2023
Q2 | $1 | Sell |
1
-3,739
| -100% | -$4.75K | ﹤0.01% | 8814 |
|
|
2023
Q1 | $3.96K | Sell |
3,740
-527
| -12% | -$1K | ﹤0.01% | 8250 |
|
|
2022
Q4 | $10K | Sell |
4,267
-1,273
| -23% | -$3.19K | ﹤0.01% | 8583 |
|
|
2022
Q3 | $24K | Buy |
5,540
+5,539
| +553,900% | +$30.3K | ﹤0.01% | 7184 |
|
|
2022
Q2 | $0 | Sell |
1
-1,006
| -100% | -$5.28K | ﹤0.01% | 11772 |
|
|
2022
Q1 | $9K | Buy |
1,007
+501
| +99% | +$4.77K | ﹤0.01% | 8634 |
|
|
2021
Q4 | $6K | Buy |
506
+505
| +50,500% | +$7.25K | ﹤0.01% | 9361 |
|
|
2021
Q3 | $0 | Sell |
1
-151
| -99% | -$2.49K | ﹤0.01% | 10827 |
|
|
2021
Q2 | $3K | Buy |
152
+86
| +130% | +$1.64K | ﹤0.01% | 8912 |
|
|
2021
Q1 | $2K | Buy |
+66
| New | +$1.98K | ﹤0.01% | 8730 |
|
|
2020
Q4 | – | Sell |
-252
| Closed | -$4.93K | – | 9196 |
|
|
2020
Q3 | $9K | Buy |
252
+87
| +53% | +$3.22K | ﹤0.01% | 6992 |
|
|
2020
Q2 | $7K | Buy |
165
+67
| +68% | +$2.61K | ﹤0.01% | 7264 |
|
|
2020
Q1 | $4K | Buy |
98
+38
| +63% | +$5.38K | ﹤0.01% | 7456 |
|
|
2019
Q4 | $10K | Buy |
60
+42
| +233% | +$10.4K | ﹤0.01% | 7321 |
|
|
2019
Q3 | $7K | Buy |
+18
| New | +$8.45K | ﹤0.01% | 7381 |
|
|
2019
Q2 | – | Sell |
-6
| Closed | -$5.27K | – | 8504 |
|
|
2019
Q1 | $7K | Buy |
+6
| New | +$6.96K | ﹤0.01% | 7057 |
|
|
2018
Q4 | – | Sell |
-12
| Closed | -$17.4K | – | 8694 |
|
|
2018
Q3 | $18K | Buy |
12
+10
| +500% | +$14.7K | ﹤0.01% | 6881 |
|
|
2018
Q2 | $3K | Sell |
2
-2
| -50% | -$11K | ﹤0.01% | 7691 |
|
|
2018
Q1 | $45K | Hold |
4
| – | – | ﹤0.01% | 5798 |
|
|
2017
Q4 | $58K | Buy |
4
+1
| +33% | +$23.1K | ﹤0.01% | 5728 |
|
|
2017
Q3 | $84K | Buy |
3
+1
| +50% | +$30.7K | ﹤0.01% | 5428 |
|
|
2017
Q2 | $93K | Hold |
2
| – | – | ﹤0.01% | 5218 |
|
|
2017
Q1 | $128K | Hold |
2
| – | – | ﹤0.01% | 4934 |
|
|
2016
Q4 | $159K | Hold |
2
| – | – | ﹤0.01% | 4959 |
|
|
2016
Q3 | $303K | Sell |
2
-1
| -33% | -$125K | ﹤0.01% | 4261 |
|
|
2016
Q2 | $323K | Buy |
3
+1
| +50% | +$118K | ﹤0.01% | 4215 |
|
|
2016
Q1 | $294K | Hold |
2
| – | – | ﹤0.01% | 4198 |
|
|
2015
Q4 | $281K | Hold |
2
| – | – | ﹤0.01% | 4409 |
|
|
2015
Q3 | $334K | Buy |
2
+1
| +100% | +$234K | ﹤0.01% | 4214 |
|
|
2015
Q2 | $301K | Buy |
+1
| New | +$264K | ﹤0.01% | 4517 |
|
Other funds holding NVIV
UBS Group's NVIV Position: Q1 2024 in Review
UBS Group sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 1 share — an estimated $1 sold.
UBS Group first reported a position in NVIV in Q2 2015 and held it in 32 quarters. The position peaked at $334K in Q3 2015. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.
- UBS Group reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
- UBS Group sold 1 InVivo Therapeutics Holdings Corp share in Q1 2024, an estimated $1.
- UBS Group first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 32 quarters.
- UBS Group's InVivo Therapeutics Holdings Corp position peaked at $334K in Q3 2015.
- 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.
Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.